Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 1
1974 2
1975 6
1976 2
1977 3
1978 1
1980 1
1981 2
1982 2
1983 3
1984 5
1985 3
1986 4
1987 4
1988 6
1989 7
1990 7
1991 6
1992 2
1993 15
1994 4
1995 7
1996 11
1997 7
1998 6
1999 7
2000 12
2001 7
2002 9
2003 6
2004 11
2005 8
2006 10
2007 8
2008 10
2009 11
2010 9
2011 15
2012 26
2013 30
2014 37
2015 30
2016 34
2017 38
2018 40
2019 42
2020 222
2021 258
2022 106
2023 65
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: Clinical Study, Clinical Trial, Evaluation Study, Meta-Analysis, Observational Study, Pragmatic Clinical Trial, Randomized Controlled Trial, in the last 1 year. Clear all
Page 1
Hydroxychloroquine for Non-Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Lucchetta R, Matuoka JY, Oliveira Junior HA, Oliveira G, Cavalcanti AB, Azevedo L, Berwanger O, Lopes RD, Rosa RG, Veiga VC, Avezum Á. Lucchetta R, et al. Arq Bras Cardiol. 2023 Apr 7;120(4):e20220380. doi: 10.36660/abc.20220380. eCollection 2023. Arq Bras Cardiol. 2023. PMID: 37042856 Free PMC article. English, Portuguese.
BACKGROUND: Previous systematic reviews have identified no benefit of hydroxychloroquine and chloroquine in non-hospitalized COVID-19 patients. ...BACKGROUND: Previous systematic reviews have identified no benefit of hydroxychloroquine and chloroquine in non-hospita …
BACKGROUND: Previous systematic reviews have identified no benefit of hydroxychloroquine and chloroquine in non-hospitalized COVID-19 …
Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial.
Gheet FS, Dawoud HE, El-Shahaby WA, Elrifaey SM, Abdelnabi HH. Gheet FS, et al. Eur J Pediatr. 2023 Apr;182(4):1685-1695. doi: 10.1007/s00431-023-04837-0. Epub 2023 Feb 8. Eur J Pediatr. 2023. PMID: 36752895 Free PMC article. Clinical Trial.
Hydroxychloroquine (HCQ) is an antimalarial agent used to treat mucocutaneous, musculoskeletal, constitutional manifestations of systemic lupus erythematosus (SLE). ...CLINICALTRIALS: gov/ with trial registration number (TRN): NCT03687905, September 2018 "retrospectively r
Hydroxychloroquine (HCQ) is an antimalarial agent used to treat mucocutaneous, musculoskeletal, constitutional manifestations of syst
Combined use of total glucosides of paeony and hydroxychloroquine in primary Sjogren's syndrome: A systematic review.
Zhang A, Chen S, Lin R. Zhang A, et al. Immun Inflamm Dis. 2023 Oct;11(10):e1044. doi: 10.1002/iid3.1044. Immun Inflamm Dis. 2023. PMID: 37904705 Free PMC article. Review.
OBJECTIVE: To assess the effectiveness and safety of the total glucosides of paeony (TGP) combined with hydroxychloroquine (HCQ) on the treatment of primary Sjogren's syndrome (pSS) by conducting a meta-analysis. ...
OBJECTIVE: To assess the effectiveness and safety of the total glucosides of paeony (TGP) combined with hydroxychloroquine (HCQ) on t …
Hydroxychloroquine significantly decreases the risk of preeclampsia in pregnant women with autoimmune disorders: a systematic review and meta-analysis.
Liu Y, Wei Y, Zhang Y, Yang H. Liu Y, et al. Clin Rheumatol. 2023 May;42(5):1223-1235. doi: 10.1007/s10067-022-06496-2. Epub 2023 Feb 2. Clin Rheumatol. 2023. PMID: 36729357
This meta-analysis aimed to investigate whether hydroxychloroquine (HCQ) intervention could decrease the incidence of preeclampsia and other maternal and fetal outcomes among pregnant women with autoimmune disorders. ...Data on maternal or fetal outcomes of the control and …
This meta-analysis aimed to investigate whether hydroxychloroquine (HCQ) intervention could decrease the incidence of preeclampsia an …
Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.
Hong H, Friedland A, Hu M, Anstrom KJ, Halabi S, McKinnon JE, Amaravadi R, Rojas-Serrano J, Abella BS, Portillo-Vázquez AM, Woods CW, Hernandez AF, Boulware DR, Naggie S, Rajasingham R. Hong H, et al. BMJ Open. 2023 Jun 16;13(6):e065305. doi: 10.1136/bmjopen-2022-065305. BMJ Open. 2023. PMID: 37328184 Free PMC article.
OBJECTIVE: We studied the safety and efficacy of hydroxychloroquine (HCQ) as pre-exposure prophylaxis for COVID-19 in healthcare workers (HCWs), using a meta-analysis of randomised controlled trials (RCTs). ...
OBJECTIVE: We studied the safety and efficacy of hydroxychloroquine (HCQ) as pre-exposure prophylaxis for COVID-19 in healthcare work …
Hydroxychloroquine and Cardiovascular Events in Patients with Rheumatoid Arthritis.
Cordova Sanchez A, Khokhar F, Olonoff DA, Carhart RL. Cordova Sanchez A, et al. Cardiovasc Drugs Ther. 2024 Apr;38(2):297-304. doi: 10.1007/s10557-022-07387-z. Epub 2022 Oct 5. Cardiovasc Drugs Ther. 2024. PMID: 36197529 Free PMC article.
Some studies have reported a decrease in CVD in patients with RA using hydroxychloroquine (HCQ). Most of these have had fewer participants and have analyzed only composite outcomes. ...
Some studies have reported a decrease in CVD in patients with RA using hydroxychloroquine (HCQ). Most of these have had fewer partici …
Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate.
Pradelle A, Mainbourg S, Provencher S, Massy E, Grenet G, Lega JC. Pradelle A, et al. Biomed Pharmacother. 2024 Feb;171:116055. doi: 10.1016/j.biopha.2023.116055. Epub 2024 Jan 2. Biomed Pharmacother. 2024. PMID: 38171239 Free article.
BACKGROUND: During the first wave of COVID-19, hydroxychloroquine (HCQ) was used off-label despite the absence of evidence documenting its clinical benefits. ...
BACKGROUND: During the first wave of COVID-19, hydroxychloroquine (HCQ) was used off-label despite the absence of evidence documentin …
Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study.
In 't Veld AE, Grievink HW, van der Plas JL, Eveleens Maarse BC, van Kraaij SJW, Woutman TD, Schoonakker M, Klarenbeek NB, de Kam ML, Kamerling IMC, Jansen MAA, Moerland M. In 't Veld AE, et al. Immunol Res. 2023 Aug;71(4):617-627. doi: 10.1007/s12026-023-09367-3. Epub 2023 Feb 22. Immunol Res. 2023. PMID: 36811819 Free PMC article. Clinical Trial.
Based on its wide range of immunosuppressive properties, hydroxychloroquine (HCQ) is used for the treatment of several autoimmune diseases. ...
Based on its wide range of immunosuppressive properties, hydroxychloroquine (HCQ) is used for the treatment of several autoimmune dis …
The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan.
Learoyd AE, Arnold L, Reid F, Beckley-Hoelscher N, Casian A, Sangle S, Morton N, Nel L, Cape A, John S, Kim S, Shivapatham D, Luqmani R, Jayne D, Galloway J, Douiri A, D'Cruz D; HAVEN study group. Learoyd AE, et al. Trials. 2023 Apr 6;24(1):261. doi: 10.1186/s13063-023-07108-3. Trials. 2023. PMID: 37024906 Free PMC article.
There is an unmet need for safer effective treatments for these patients. Hydroxychloroquine is being explored due to its effect in similar autoimmune conditions such as systemic lupus erythematosus. ...Hydroxychloroquine is safer, cheaper and has fewer adverse effe …
There is an unmet need for safer effective treatments for these patients. Hydroxychloroquine is being explored due to its effect in s …
Protective effect of hydroxychloroquine on infections in patients with systemic lupus erythematosus: an observational study using the LUNA registry.
Hidekawa C, Yoshimi R, Saigusa Y, Tamura J, Kojitani N, Suzuki N, Sakurai N, Yoshioka Y, Sugiyama-Kawahara Y, Kunishita Y, Kishimoto D, Higashitani K, Sato Y, Komiya T, Nagai H, Hamada N, Maeda A, Tsuchida N, Hirahara L, Soejima Y, Takase-Minegishi K, Kirino Y, Yajima N, Sada KE, Miyawaki Y, Ichinose K, Ohno S, Kajiyama H, Sato S, Shimojima Y, Fujiwara M, Nakajima H. Hidekawa C, et al. Front Immunol. 2023 Sep 1;14:1227403. doi: 10.3389/fimmu.2023.1227403. eCollection 2023. Front Immunol. 2023. PMID: 37720209 Free PMC article.
OBJECTIVES: Infection is a leading cause of death in patients with systemic lupus erythematosus (SLE). Alt hough hydroxychloroquine (HCQ) has been reported to inhibit infection, evidence from Asian populations remains insufficient. ...
OBJECTIVES: Infection is a leading cause of death in patients with systemic lupus erythematosus (SLE). Alt hough hydroxychloroquine ( …
50 results